Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Gillessen, Silke; Omlin, Aurelius; Attard, Gerhardt; Bono, Johann S. de; Efstathiou, Eleni; Fizazi, Karim; Halabi, Susan; Nelson, Peter B.; Smith, M. R.; Soule, Howard R.; Akaza, Hideyuki; Beer, T. M.; Beltran, H.; Chinnaiyan, Arul M.; Daugaard, Gedske; Davis, Ian D.; Santis, M. De; Drake, Charles G.; Eeles, Rosalind; Fanti, Stefano; Gleave, Martin; Heidenreich, Axel; Hussain, Muhammad Musharraf; James, Nicholas D.; Lecouvet, Frédéric; Logothetis, C.; Mastris, Ken; Nilsson, Staffan; Oh, Wangensteen; Olmos, David; Padhani, Anwar R.; Parker, Catherine; Rubin, Mark A.; Schalken, J. A.; Scher, Howard I.; Sella, Avishai; Shore, Neal D.; Small, Eric J.; Sternberg, C.; Suzuki, Hidetaka; Sweeney, C. J.; Tannock, Ian F.; Tombal, Bertrand

doi:10.1093/annonc/mdw180

Cited by 29 publications

(33 citation statements)

References 68 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 AR plays an important role in the treatment of mCRPC. 6 Recently, one study reported that members of the 14-3-3 family play an important role in the development and progression of PCa by regulating the transcription of PSA through the AR. 8 14-3-3ε belongs to the 14-3-3 family, which was first identified in mammalian brain tissues by Moor and Perez in 1968.…”

Section: Discussionmentioning

confidence: 99%

“…Generally, treatment with androgen ablation eventually leads to AIPC. 5 Although the androgen receptor (AR) is an effective way to treat metastatic castrate-resistant prostate cancer (mCRPC), 6 29,430 people died of PCa in the USA in 2018. 7 AR is a ligand-activated transcription factor that regulates numerous target genes, including prostate-specific antigen (PSA).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway

Zhao

Duan

et al. 2020

CMAR

View full text Add to dashboard Cite

Introduction: Prostate cancer (PCa) is one of the most common malignancies, and almost all patients with advanced PCa will develop castration-resistant prostate cancer (CRPC) after receiving endocrine therapy. Effective treatment for patients with CRPC has not been established. Novel approaches are needed to identify therapeutic targets for CRPC. Purpose: Recent research studies have found that members of the 14-3-3 family play an important role in the development and progression of PCa. Previous results have shown that 14-3-3 ɛ is significantly upregulated in several cancers. This study aimed to identify novel miRNAs that regulate 14-3-3 ɛ expression and therapeutic targets for CRPC. Methods: In this study, we used computation and experimental approaches for the prediction and verification of the miRNAs targeting 14-3-3 ɛ, and investigated the potential roles of 14-3-3 ɛ in the survival and proliferation of 22RV1 cells. Results: We confirm that mir-31-5p is downregulated in 22RV1 cells and acts as a tumor suppressor by regulating 14-3-3 ɛ. Ectopic expression of miR-31-5p or 14-3-3 ɛ interference significantly inhibits cell proliferation, invasion, and migration in 22RV1 cells, as well as promotes cell apoptosis via the PI3K/AKT/Bcl-2 signaling pathway. Moreover, 14-3-3 ɛ is required for the miR-31-5p-mediated upregulation of the PI3K/AKT/Bcl-2 signaling pathway. Conclusion: Our findings provide information on the underlying mechanisms of miR-31-5p/14-3-3 ɛ in 22RV1 cell proliferation and apoptosis through the PI3K/AKT/Bcl-2 signaling pathway. These results suggest that miR-31-5p and 14-3-3 ɛ may potentially be utilized as novel prognostic markers and therapeutic targets for PCa treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway

Zhao

Duan

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…CAB in the third-line is recommended by 73% of the APCCC panel in a majority of patients, while 24% recommended it in a minority of selected patients [15]. Recommendations of fourth-line and beyond therapy were not given.…”

Section: Discussionmentioning

confidence: 99%

Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review

Hardenberg

Schwartz²,

Werner³

et al. 2017

Urol Int

View full text Add to dashboard Cite

Background: Limited data are available for the use of agents in metastatic castration-resistant prostate cancer (mCRPC) beyond the third-line. We provide data during treatment with cabazitaxel (CAB), helping to improve the informed-consent process. Patients and Methods: We retrospectively reviewed patients treated with fourth-line or beyond CAB for mCRPC after failure of previous therapies with docetaxel, abiraterone acetate, enzalutamide and/or radium-223. The progression-free survival (PFS) and the overall survival (OS) were estimated using the Kaplan-Meier method and compared to published data based on a structured literature review. The hospitalization rate was recorded. Factors influencing 6-months OS were analyzed. Results: Fifteen patients were identified at 4 institutions and included in the analysis. The median PFS was 104 days (range 47-397 days). The median time to death was 10 months (range 2-16). PFS and OS data are in accordance with 17 published patients so far. During the therapy, eleven (73%) of the patients were hospitalized. Prostate-specific antigen (PSA, 500 units; hazards ratio [HR] 1.491, 95% CI 1.000-2.0175), white blood cell count (HR 0.425, 95% CI 0.108-0.952), hemoglobin (HR 0.6014, 95% CI 0.2942-1.0758), and alkaline phosphatase (100 units; HR 1.0964, 95% CI 1.000-1.2859) correlate with 6-months OS. Conclusions: CAB beyond the third-line is often accompanied by hospitalization. PFS is a significant proportion of the median time of OS. The baseline laboratory might be a good indicator for the decision between CAB and best-supportive care.

show abstract

“…[1][2][3] In general, ADT is achieved by surgery, drug-based monotherapy, or combined androgen blockade (CAB). [3][4][5][6] ADT results in a marked decrease in the prostate-specific antigen (PSA) level and shows a good tumor reduction effect in most cases. 7 However, the PSA may be found to gradually increase even when the testosterone value is at a castration level.…”

Section: Introductionmentioning

confidence: 99%

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching

et al. 2018

View full text Add to dashboard Cite

BackgroundThis study investigated how differences in the method of the first‐line androgen deprivation therapy (ADT) affected the time to castration‐resistant prostate cancer.MethodsThe Japan Study Group of Prostate Cancer compiled a nationwide community‐based database on prostate cancer patients who underwent ADT. That database included 13 774 patients who were started on ADT by surgical or medical castration alone (monotherapy group, 5395 cases) or ADT in combination with a nonsteroidal anti‐androgen (combined androgen blockade (CAB) group, 8379 cases). We used logistic regression analysis with background factors as independent factors to calculate propensity scores in regard to selection of CAB. Next, for 8826 cases of propensity score‐matched patients, we compared the survival rates in the two groups.ResultsThe CAB group showed a significantly better progression‐free survival (PFS) rate (65.6% vs 59.6% at 5 years; median time to progression, 11.6 vs 7.1 years; hazard ratio in the CAB group: 0.78, with a 95% confidence interval of 0.72 to 0.84; P < 0.001). In subgroup analysis based on the background factors, the PFS rate was generally better in the CAB group in all risk subgroups except for those having significant risk factors.ConclusionPropensity score matching analysis revealed the prolongation of PFS by CAB in prostate cancer patients without significant risk factors. It would possible to decide the type of the first‐line ADT according to the prostate cancer risk.

show abstract

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

Cited by 29 publications

References 68 publications

<p>miR-31-5p Regulates <em>14-3-3 ɛ</em> to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway</p>

<p>miR-31-5p Regulates <em>14-3-3 ɛ</em> to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway</p>

Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community‐based multi‐institutional database across Japan using propensity score matching

Contact Info

Product

Resources

About